Multimodal Orthognathic Study Comparing Use of Exparel With Standard of Care.
- Conditions
- Pain, Postoperative
- Interventions
- Registration Number
- NCT06499181
- Lead Sponsor
- United States Naval Medical Center, San Diego
- Brief Summary
A prospective, randomized clinical trial to determine if using liposomal bupivicaine in maxillary orthognathic procedures can reduce the post-operative use of opioids as well as improving the patient's quality of life, versus traditional bupivicaine alone.
- Detailed Description
A prospective randomized clinical trial to determine if using liposomal bupivicaine in maxillary orthognathic procedures can reduce the post-operative use of opioids as well as improving the patient's quality of life versus traditional bupivicaine alone. A total of 100 patients who would ordinarily undergo maxillary orthognathic procedures will be randomized into 2 groups. One group will receive 133mg of Exparel (must limit volume of product due to spaces involved and other studies in oral surgery have used 133mg) at the completion of the procedure while the control group receives 50 mg of bupivicaine at the completion of the procedure as is typical standard of care. The injections will be made in similar regions near the incision lines. No other differences will be made between the groups. Perioperative anesthesia will consist of non-opioid techniques, and patients will be monitored post-operatively during a 1 night hospital admission. Patients will complete an anonymous daily diary for 7 days. The diary will consist of information regarding pain scores, quality of life (nausea, swelling, oral function, etc) and medicines taken.
At one week post op the participant will return to the clinic where they will fill out a final questionnaire discussing the previous week's experience regarding the topics of the questionnaires.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 86
- Male or female 18 years or older
- Scheduled for Maxillary Orthognathic Surgery
- American Society of Anesthesiologists classification 1,2,3
- Able to provide consent, adhere to study schedule, complete study journal
1 History of hypersensitivity or idiosyncratic reaction to amide-type local anesthetics or opioids.
2 Contraindication to lidocaine, epinephrine, bupivacaine, or oxycodone
3 Significant drug allergy history
4 Positive result from urine drug screen at pre-op visit
5 Currently pregnant or nursing at time of study or within 1 month of drug administration
6 Severe renal or hepatic impairment, significant cardiovascular disease; migraines, frequent headaches
7 Use of any of the following medication within 1 month of liposomal bupivacaine infiltration or if the medications are being given to control pain: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin Nonadrenaline Reuptake Inhibitors (SNRIs), gabapentin, pregabalin, or duloxetine.
8 Current use of systemic glucocorticosteroids within 1 month of enrollment in the study.
9 No concurrent procedures with 2 weeks before or after orthognathic procedure
10 No more than 1 previous surgery for similar condition or diagnosis.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control Group Bupivacaine Bupivacain The control arm will be injected with 10cc of 0.5% bupivacaine (50 mg) with 1:50,000 epinephrine near to the incision site one time only at the completion of the procedure per standard procedure. Experimental Group Exparel Liposomal bupivacaine The experimental arm will be injected with 133mg (10cc) of liposomal bupivacaine (Exparel) near to the incision site one time only at the completion of the procedure. Control Group Bupivacaine Epinephrin The control arm will be injected with 10cc of 0.5% bupivacaine (50 mg) with 1:50,000 epinephrine near to the incision site one time only at the completion of the procedure per standard procedure.
- Primary Outcome Measures
Name Time Method Differences in post-op opioid consumption between local Exparel infiltration and bupivacaine in maxillary orthognathic procedures. Daily up to seven days post operative procedure. The primary objective is to examine differences in post-operative opioid consumption between the two groups
- Secondary Outcome Measures
Name Time Method Post-operative sleeping quality. Daily up to seven days post operative procedure. The Epworth Sleepiness Scale will be used to ascertain the quality of sleep. Eight situations are presented with the participant choosing the following responses:
No chance of dozing = 0 Slight chance of dozing = 1 Moderate chance of dozing = 2 High chance of dozing = 3
The higher the combined score the poorer the quality of sleep.Post operative quality of life. Daily up to seven days post operative procedure. Post operative quality of life was ascertained with the 10 point Likert scaled question, "What is your rating for your actual overall comfort?'. 1 = Very low overall comfort, 5 = Neither low or high overall comfort, 10 = Very high overall comfort.
The higher the score means a better outcome.Post-operative nausea and vomiting Daily up to seven days post operative procedure. Examine the number of times per day the participant experiences nausea and/or vomiting.
Post operative swelling. Day of surgery and on post operative procedure day seven. Photos comparing cheek and lower jaw swelling with a millimeter ruler taken on day of surgery post operative procedure and one week post operative procedure clinic visit will be made by clinician per standard of care.
Post operative oral function. Day of surgery and at seventh day post operative procedure. Clinician will assess occlusion and midline symmetry on day of surgery post operative procedure and at one week post operative procedure clinic visit per standard of care with the aid of photographs using a millimeter ruler.
Trial Locations
- Locations (1)
Naval Medical Center San Diego
🇺🇸San Diego, California, United States